drugset
drugset / Trial / NCT04054921

Safety Study for Beta Thalassemia Subjects on PTG-300

NCT04054921 ↗

Phase 2 Completed 34 enrolled Protagonist Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

Timeline

Start
2019-05-10
Primary completion
2020-07-31
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rusfertide Peptide 80 mg —

Indications

beta thalassemia